Crossmark

Clinical and cost-effectiveness analysis of carbapenems versus ciprofloxacin in the treatment of urinary tract infections due to extended spectrum β-lactamase-producing Enterobacterales

Crossref DOI link: https://doi.org/10.1007/s00228-023-03450-2

Published Online: 2023-01-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Barnawi, Marwah H.

Thabit, Abrar K.

Almasri, Diena M.

Bulbol, Suha
License Information

Text and Data Mining valid from 2023-01-11

Version of Record valid from 2023-01-11
More Information

Article History

Received: 3 October 2022

Accepted: 2 January 2023

First Online: 11 January 2023

Declarations

:

: The institutional review board at John Hopkins Aramco Healthcare approved the study protocol (reference no. 18–15).

: The authors declare no competing interests.

Document is current

Any future updates will be listed below